Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chart is starting to look like the previous Feb-March setup. Worth watching with quarterly coming up.
Please post anything identifying this company as a real investment. Your DD must be based on something, and we would love to know why you think the Nuerosync or other products are going anywhere.
Did my DD and I ran away as fast as possible.
It's listed as a sale...Form t...16:05 (after market close)...and the price went down for that transaction. Picked Up shares? That might not be 100% correct.
Definitely agree with that. I don't like the low-volume days before a breakout, but I am loving this chart set-up.
30 Day RSI about to cross the 20 oversold level, and the narrowing of the 10 day bollinger bands are really starting to look positive.
If you can get a total on the T-trades, that would be awesome. It would just be nice to find out how much manipulative financing is happening. I really couldn't wait much longer, so I stepped out of GAWK for a bit to chase down some biotechs. I like this company's ambition to grow in cloud resources, but their financing strategies are definitely hurting. I just needed some wins. Maybe worth a try again if they can stop the bleeding.
Kind of a strange last minute 100 share sale bringing this one down 7%. Not to be selfish, but I'm really trying to beat Timothy Sykes this year. I just need this one to pop 20%, and I'll be ahead again.
$ORPN - Great Potential. Initiation of the Phase 2b trial with trehalose IV solution while the stock is near 52 week lows.
I like the corporate update. Initiation of the Phase 2b trial with trehalose IV solution while the stock is near 52 week lows should attract some attention.
Hello again,
I'm really not trying to ride your coattails. I've been slowly adjusting my alerts for oversold biotechs with good one-year volatility. Seems like every time I find one, you're already on it.
It was between ORPN and CYTX (may take longer to gain confidence back after the offer and split), and ORPN won for best possible up-swing.
Overall, good results, and I really can't wait to see how the implementation in Japan goes. Glad I found this company for so cheap.
Able to get in at 2.01. Been watching a while for this to be oversold with good news.
I saw a similar reaction to the Greek debt crisis in August. Had nothing to do with biotechs, but I still took a hit. If this does go the way of the overall market, I think this will be a good average-down candidate.
We might hit some speed bumps with the overall decline coming from the British reaction. I can see the futures are already hurting everything after the Pound started declining.
Right there with you. The last thing the investors heard was from the parasitic class action lawyers. The company should release something about their other research to get investors attention back.
I guess this is the drawback from the 1.87 to 2.15 climb. Waiting for bigger and better bounces considering the valuation and prices two weeks ago.
No debt...cash and assets with outstanding shares should value this one above 4 for sure.
Nice early run with a continuation pattern forming. Let's see if this holds while everyone realizes it's undervalued.
It really shows the confidence the receiving company's have in the future value of their shares. For example, NetD Consulting received over 25 million in convertible shares in exchange for services. At the time of receipt, the shares would have been worth between $75K and $150k. I would be surprised if they still had any shares.
My blocks spread between 2.01 and 1.99, and I'm happy. Definitely anticipating a correction back to at least what the balance sheet reflects.
Definitely scraped by on that one. Descent move, but I don't think I'll trade into a delisting notice again. No way to see that move by Roth coming.
Starting to look like the formation of a continuation pattern on an upward trend...
I hate trying to gauge the bottom of a trend. I've got more ready to buy, just need the elusive reversal to happen.
Definitely too low and oversold. I got all mine in finally around 0.619.
Probably a good call. For the month chart it looks like a drawback from the earlier jump. Buyers at .0035 probably want to move on.
Bulls walk up stairs and bears jump out the window.
I'm testing this one out with a few thousand shares. I'm not thinking the delisting warning will not impact that much.
Thanks for the elementary lesson in stock analysis. "NET LOSS = NOT GOOD." (Seriously?) Most people investing in this company are looking more at the expenditures for acquisitions and revenue.
I take a lot of biopharmaceutical companies for big rides, and almost all of them post net losses during growth and research periods.
However, thanks for the input.
Does the delisting announcement adversely affect the possibility of a rebound?
Over 200 million. I guess you have consider what the total company is worth and divide.
Are you out at the morning peak, or holding for 1.30s?
Interesting PR for the investor conference.
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11409966&RcvdDate=5/25/2016&CoName=DIGITAL%20TURBINE%2C%20INC.&FormType=8-K&View=html
Could this be the cause of increased interest in APPS?
Hello $1.00.
Haha. People were seriously trying to take out profits that early?
I didn't lose much on this long-shot, but it was enough to give me a new idea...I'm creating a new neuro-sensing brain-computer interface device. It's basically a wire you shove up your nose and connect to your Iphone headphone jack. Preliminary tests show it is more effective than Nuerosync, and I will offer 30 billion shares to start. Goodbye Mind Solutions. Rest in Agony Fouch, Driscoll, and Burt.
Annual report posted. Awesome! Highlights: Now has shareholder equity, 202% profit increase, 885% revenue increase.
I guess there will be some profit taking drawbacks before it breaks 1.00. Any thoughts on whether this is a long run to 1.20 we've been waiting for?
I double checked last year. They announced a late annual report and didn't file until July. No big deal then.
Hopefully it's time to swing again. Nasdaq goes up 57 points while this one flounders. Getting a little tired of this one.
Quarterly is out. The separation agreement with the previous CEO did cost 4.3 million, but at least it wasn't a continuing cost. Also, I like that ONT-380 research funding increased. Still liking this company for a long position.
Anyone else tired of the impenetrable ceiling of .004? Need some buying pressure to bring the volume.
Hit my average down target of .0746. I guess now I'm just waiting for the short interest to dissipate.